The board of direcctors of ClouDr Group Limited announced that the launch of Hetangjin Dapagliflozin Tablets, a proprietary product of the Group of which the Group has sales rights, was held on March 9, 2024, marking the commencement of the marketing of the product after it officially obtained the drug registration certificate (Guo Yao Zhun Zi No. H20234636) from the National Medical Products Administration (Guo Jia Yao Pin Jian Du Guan Li Ju) of China on December 13, 2023. Dapag liflozin Tablets are the only basic drug in the sodium-glucose cotransporter 2 ("SGLT-2") inhibitor class.

Dapagliflozin tablets were approved for entry into the Chinese market in 2017, and were included as a category B drug in the basic medical insurance drug catalog in China in 2019, with annual sales in China reaching approximately RMB 7 billion in 2023. As an SGLT-2 inhibitor, DapagliflozinTablets are a first-line medication for improving glycemic control in adult patients with type 2 diabetes. Several studies have shown that Dapagliflozin tabletsts can comprehensively manage multiple risk factors for cardiac and renal diseases, and are effective in lowering glycated hemoglobin, reducing body weight, lowering uric acid, lowering urinary albumin-to-creatinine ratio, and lowering systolic blood pressure.

This type of SGLT-2 inhibitor achieved breakthroughs in body weight reduction and the prevention and treatment of cardiovascular and renal diseases, which have considerable cross-domain value. Hetangjin Dapagliflozin Tablet have broken through the patent restrictions on the crystalline form in the original research, and have been launched ahead of the original schedule in accordance with relevant laws and regulations as a generic product of Dapagliflozintablets in China. With the launch of HetangJ Dapaglif Lozin Tablets, the Group will leverage its extensive hospital network and offline pharmacy network for marketing and sales of the product, to digitally develop a broad market for the product in an efficient manner, to maximize the effect of the product on improving the quality of life of patients with chronic diseases, and to enhance the patient accessibility of quality pharmaceutical products.

The Board is of the view that the launch of HetANGjin Dapag Liflozin Tablets is a strong evidence of the Company's patient-to-industry model, which is expected to have a positive impact on the Company's financial performance and long-term development. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.